Palliative appropriateness criteria: external validation of a new method to evaluate the suitability of palliative radiotherapy fractionation
- PMID: 36625853
- PMCID: PMC9938013
- DOI: 10.1007/s00066-022-02040-y
Palliative appropriateness criteria: external validation of a new method to evaluate the suitability of palliative radiotherapy fractionation
Abstract
Background: Recently, the palliative appropriateness criteria (PAC) score, a novel metric to aid clinical decision-making between different palliative radiotherapy fractionation regimens, has been developed. It includes baseline parameters including but not limited to performance status. The researchers behind the PAC score analyzed the percent of remaining life (PRL) on treatment. The latter was accomplished by calculating the time between start and finish of palliative radiotherapy (minimum 1 day in case of a single-fraction regimen) and dividing it by overall survival in days from start of radiotherapy. The purpose of the present study was to validate this novel metric.
Patients and methods: The retrospective validation study included 219 patients (287 courses of palliative radiotherapy). The methods were identical to those employed in the score development study. The score was calculated by assigning 1 point each to several factors identified in the original study and using the online calculator provided by the PAC developers.
Results: Median survival was 6 months and death within 30 days from start of radiotherapy was recorded in 13% of courses. PRL on treatment ranged from 1 to 23%, median 8%. Significant associations were confirmed between online-calculated PAC score, observed survival, and risk of death within 30 days from the start of radiotherapy. Patients with score 0 had distinctly better survival than all other groups. The score-predicted median risk of death within 30 days from start of radiotherapy was 22% in our cohort. A statistically significant correlation was found between predicted and observed risk (p < 0.001). The original and present study were not perfectly concordant regarding number and type of baseline parameters that should be included when calculating the PAC score.
Conclusion: This study supports the dual strategy of PRL and risk of early death calculation, with results stratified for fractionation regimen, in line with the original PAC score study. When considering multifraction regimens, the PAC score identifies patients who may benefit from shorter courses. Additional work is needed to answer open questions surrounding the underlying components of the score, because the original and validation study were only partially aligned.
Keywords: 30-day mortality; Bone metastases; Brain metastases; Prognostic factors; Radiation therapy.
© 2023. The Author(s).
Conflict of interest statement
C. Nieder, E.C. Haukland, B. Mannsåker, and A. Dalhaug declare that they have no competing interests.
Figures
Similar articles
-
Early death after palliative radiation treatment: 30-, 35- and 40-day mortality data and statistically robust predictors.Radiat Oncol. 2023 Apr 3;18(1):59. doi: 10.1186/s13014-023-02253-0. Radiat Oncol. 2023. PMID: 37013643 Free PMC article.
-
Percent of remaining life on palliative radiation treatment: solely a function of fractionation?Rep Pract Oncol Radiother. 2023 Apr 6;28(1):47-53. doi: 10.5603/RPOR.a2023.0013. eCollection 2023. Rep Pract Oncol Radiother. 2023. PMID: 37122907 Free PMC article.
-
Palliative Appropriateness Criteria: A Pragmatic Method to Evaluate the Suitability of Palliative Radiotherapy Fractionation.J Palliat Med. 2023 Jan;26(1):67-72. doi: 10.1089/jpm.2022.0173. Epub 2022 Jul 26. J Palliat Med. 2023. PMID: 35881861 Free PMC article.
-
International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control.Clin Lung Cancer. 2012 May;13(3):225-35. doi: 10.1016/j.cllc.2011.11.002. Epub 2011 Dec 13. Clin Lung Cancer. 2012. PMID: 22169482
-
Clinical results of unconventional fractionation radiotherapy in central nervous system tumors.Tumori. 1998 Mar-Apr;84(2):176-87. doi: 10.1177/030089169808400215. Tumori. 1998. PMID: 9620243 Review.
Cited by
-
Early death after palliative radiation treatment: 30-, 35- and 40-day mortality data and statistically robust predictors.Radiat Oncol. 2023 Apr 3;18(1):59. doi: 10.1186/s13014-023-02253-0. Radiat Oncol. 2023. PMID: 37013643 Free PMC article.
-
Percent of remaining life on palliative radiation treatment: solely a function of fractionation?Rep Pract Oncol Radiother. 2023 Apr 6;28(1):47-53. doi: 10.5603/RPOR.a2023.0013. eCollection 2023. Rep Pract Oncol Radiother. 2023. PMID: 37122907 Free PMC article.
-
Stereotactic radiotherapy for patients with bone metastases: a selected group with low rate of radiation treatment during the last month of life?Radiat Oncol. 2024 Nov 1;19(1):151. doi: 10.1186/s13014-024-02547-x. Radiat Oncol. 2024. PMID: 39487535 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources